98%
921
2 minutes
20
Introduction: Intrahepatic cholestasis is a potentially serious condition that can develop during the late half of pregnancy. It can increase the risk of preterm birth and stillbirth in fetus and postpartum hemorrhage in mothers. The main symptoms are severe pruritus. Since this condition is hormone-induced, it is a reversible condition and likely to recur in subsequent pregnancy. Early diagnosis, adequate treatment, and well-timed delivery are imperative for better maternal and fetal outcomes.
Materials And Methods: This is a prospective observational study done in a tertiary care center, RIMS, Ranchi, Jharkhand. Data were collected from 203 affected pregnant females from July 2023 to June 2024. Proper history, examination, and investigations were done.
Results: The incidence was found to be 2.62% in our hospital. Women of 26-30 years were affected mostly (33.99%). 53.69% were from rural areas and belonged to the lower middle socioeconomic class. Primigravidae were affected more (45.81%). Jaundice was the most common complication (8.87%). Postpartum hemorrhage was observed in 8.87% of cases. 28.5% had preterm delivery. Intrauterine fetal death was seen in 4.43% and 1.97% had stillbirth in women affected with the disorder. Liver enzymes were significantly raised.
Conclusion: It affects the fetal outcome adversely, resulting in preterm birth, fetal distress, stillbirth, meconium aspiration, and respiratory distress syndrome. There is a high risk of postpartum hemorrhage in mothers. Proper counseling, investigations, and treatment with ursodeoxycholic acid will help in alleviating the symptoms and result in a better outcome for the mother and fetus. It is a self-limiting condition.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4103/aam.aam_100_25 | DOI Listing |
BJOG
September 2025
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.
Objective: To compare maternal and neonatal adverse outcomes between women who are English proficient (EP) and those who have limited English proficiency (LEP).
Design: Retrospective cohort study.
Setting: Single US academic medical centre with interpreter services.
Int J Obstet Anesth
September 2025
Westmead Hospital Department of Anaesthesia and Perioperative Medicine, Westmead, Australia.
Background: Maternal cardiovascular disease (CVD) is a leading cause of maternal mortality. Data on anaesthetic management in patients with CVD is limited.
Methods: This ten-year retrospective cohort study of 508 pregnancies in women with CVD, stratified by modified World Health Organization (mWHO) risk category, compared lowrisk (mWHO I-II) (n = 323) and high-risk (mWHO II to III-IV) (n = 185) groups to a control obstetric population (n = 55,153).
Hum Reprod Update
September 2025
Women's Health Research Collaborative, New York, NY, USA.
Background: Reproductive-age women with intrauterine adhesions (IUAs) following uterine surgery may be asymptomatic or may experience light or absent menstruation, infertility, preterm delivery, and/or peripartum hemorrhage. Understanding procedure- and technique-specific risks and the available evidence on the impact of surgical adjuvants is essential to the design of future research.
Objective And Rationale: While many systematic reviews have been published, most deal with singular aspects of the problem.
Int J Womens Health
August 2025
School of Nursing and Rehabilitation, Nantong University, Nantong, Jiangsu, People's Republic of China.
Background: Previous studies did not investigate the effect of gradually increasing the concentration of low-dose oxytocin on mother and newborn outcomes. The purpose of this study was to look at the relationship between oxytocin responsiveness and outcomes for both mothers and newborns during labor induction.
Methods: This retrospective cohort study was conducted at Nantong Maternal and Child Health Hospital, and participants were divided into the early reaction to oxytocin group and the later reaction to oxytocin group based on oxytocin response.
BJOG
September 2025
IQ Health Science Department, Radboud University Medical Center, Nijmegen, the Netherlands.